Ascendis Pharma A/S (ASND) Is A Stock You Should Watch

0
13
BBAI
BBAI

As of Wednesday close, Ascendis Pharma A/S’s (NASDAQ:ASND) stock was down -$1.25, moving down -1.04 percent to $118.84. The average number of shares traded per day over the past five days has been 342,680 shares. 3 times new highs have been achieved over the past 5 days, with a $3.99 gain in that time frame. In the last twenty days, the average volume was 554,215, while in the previous 50 days, it was 496,600.

Since last month, ASND stock rose 11.17%. Shares of the company fell to $100.91 on 10/27/22, the lowest level in the past month. A 52-week high of $148.80 was reached on 01/03/22 after having rallying from a 52-week low of $61.58. Since the beginning of this year, ASND’s stock price has dropped by -11.66% or -$15.69, and marked a new high 1 time. However, the stock has declined by -20.13% since its 52-week high.


Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored


Valuation Metrics

The stock’s beta is 0.53. Besides these, the trailing price-to-sales (P/S) ratio of 191.94, the price-to-book (PB) ratio of 14.18.

Financial Health

In the three months ended March 30, Ascendis Pharma A/S’s quick ratio stood at 6.80, while its current ratio was 7.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 1.18, and the total debt-to-equity ratio was 1.23. On the profitability front, the trailing twelve-month gross margin is 68.20% percent. Based on annual data, ASND earned $5.03 million in gross profit and brought in $9.2 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -45.70%. Return on equity (ROE) for the past 12 months was -73.70%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ASND’s revenue rose 10.56% during the quarter, while net income inched up to $8.71 million. While analysts expected Ascendis Pharma A/S to report -$0.02 quarterly earnings, the actual figure was -$0.14 per share. During the quarter, the company generated -$141.5 million in EBITDA. The liabilities of Ascendis Pharma A/S were 827.79 million at the end of its most recent quarter ended March 30, and its total debt was $553.24 million.

Technical Picture

This quick technical analysis looks at Ascendis Pharma A/S’s (ASND) price momentum. With a historical volatility rate of 98.89%, the RSI 9-day stood at 52.79% on 23 November.

With respect to its five-day moving average, the current Ascendis Pharma A/S price is up by +3.47% percent or $3.99. At present, ASND shares trade +16.96% above its 20-day simple moving average and +24.58% percent above its 100-day simple moving average. However, the stock is currently trading approximately +11.47% above its SMA50 and -3.73% below its SMA200.

Stochastic coefficient K was 38.25% and Stochastic coefficient D was 36.27%, while ATR was 6.38. Given the Stochastic reading of 38.53% for the 14-day period, the RSI (14) reading has been calculated as 53.65%. As of today, the MACD Oscillator reading stands at 1.24, while the 14-day reading stands at -0.99.

LEAVE A REPLY

Please enter your comment!
Please enter your name here